Alvogen, the multinational pharmaceuticals company, today announced the
launch of Inflectra™ (Infliximab) into Central and Eastern Europe.
InflectraTM, Europe's first biosimilar monoclonal
antibody (mAb) therapy that has been approved for the treatment of
inflammatory conditions including rheumatoid arthritis (RA), ankylosing
spondylitis, Crohn's disease (CD), ulcerative colitis (UC), psoriatic
arthritis (PsA) and psoriasis. Alvogen and Hospira formed a strategic
partnership in 2011 to provide the highest quality products and services
for customers and patients throughout Central and Eastern Europe (CEE).
This alliance enables us to provide increased access to the newest
biosimilar drugs with state-of-the-art technology.
Robert Wessman is the Chairman and CEO of Alvogen. In Portugese, ''alvo'' means target or goal. It also means exceptionally good, that underlines our commitment to the outstanding quality of our products and services. The latter part of our name ''gen,'' links us to the future generation and our determination to build a top-10 global next-generation pharmaceutical company.(Photo: Business Wire)
InflectraTM is a biosimilar medicine to the reference
medicinal product, RemicadeTM (Infliximab), and is the first
monoclonal antibody (mAb) to be approved through the European Medicines
Agency (EMA) biosimilars regulatory pathway. RemicadeTM
recorded European sales of over USD 2 billion in 2012.1 Alvogen
will market the product in Bulgaria, Croatia, Estonia, Hungary, Latvia,
Lithuania, Poland, and Romania.
Petar Vazharov, Executive Vice President at Alvogen in the CEE region,
commented: "We are delighted about the launch of InflectraTM.
This product represents a major milestone for our biosimilar portfolio,
which has been making great progress since its launch in partnership
with Hospira in 2011. Biosimilars offer a huge opportunity for our
business in Eastern Europe and with InflectraTM we
demonstrate the continued growth we are achieving in this important
portfolio. InflectraTM offers a more affordable - but equall
effective - treatment option for sufferers of inflammatory conditions,
offering compelling cost saving opportunities within the European Union."
Dr. Stan Bukofzer, Corporate Vice President and Chief Medical Officer
of Hospira added: "The rigorous scientific review conducted by the
European Medicines Agency and approval by the European Commission
confirms that InflectraTM has demonstrated similar quality,
efficacy and safety to RemicadeTM. For over a decade,
biologic medicines have been pivotal in treating a range of inflammatory
conditions, so the launch in Europe of InflectraTM
as a biosimilar alternative represents a huge step towards the
affordability of future biologic therapies."
The use of biologic medicines has led to vast improvements in the
efficient treatment of conditions such as RA and IBD (inflammatory bowel
disease), but these drugs are also responsible for some of the highest
medicinal costs for many countries.2 The introduction of
biosimilar mAbs in Europe is expected to deliver savings of up to €20.4
billion by 2020.3
In partnership with Hospira, Alvogen has been marketing biosimilars in
Central & Eastern Europe for a number of years, with great success.
Partnering with Hospira gives Alvogen access to a well established
biosimilar pipeline. Hospira's biosimilar portfolio includes Inflectra™
as well as two other currently marketed products in the areas of
nephrology and oncology. In addition, Hospira plans to launch a number
of new biosimilar monoclonal antibodies, one of which is currently in
late stage development. Together, Alvogen and Hospira share the
commitment to deliver the highest quality products and services to its
customers and patients.
Demonstrating its ongoing commitment to the exciting biosimilar market,
Alvogen's sister company, Alvotech, announced in November 2013 that it
would invest $250 million in biopharmaceuticals. This investment
includes the building of a state-of-the-art biopharmaceutical
development and manufacturing center in Reykjavik, Iceland and a
pipeline including six monoclonal antibodies.
Alvogen is a multinational, privately owned pharmaceuticals company
focused on developing, manufacturing and distributing generic, brand,
over-the-counter brands (OTC) and biosimilar products. With more than
200 pharmaceutical projects in development and registration, the group's
product portfolio consists of a broad range of leading molecules for the
treatment of conditions in the fields of: oncology, cardiology,
respiratory, neurology and gastroenterology. Alvogen has commercial
operations in over 30 countries with 2,000 employees. North America is
Alvogen's single largest market and other key markets include:
South-Korea, Romania, Bulgaria, Hungary, Russia and China. Visit: www.alvogen.com
Hospira Inc. is the world's leading provider of injectable drugs and
infusion technologies. Through its broad, integrated portfolio, Hospira
is uniquely positioned to Advance Wellness™ by improving patient and
caregiver safety while reducing healthcare costs. The company is
headquartered in Lake Forest, Ill., and has approximately 16,000
employees. Learn more at www.hospira.com.
1 Merck and Co, 2012 Annual Report, available from: http://www.merck.com/investors/financials/annual-reports/.
Accessed June 2013.
2 Bendtzen, K. Immunotherapy. 2012; 4(11): 1167-1179.
3 Haustein R. et al. Saving money in the European healthcare
systems with biosimilars. Generics and Biosimilars Initiative Journal.
2012; 1(3-4): 120-6.
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20140213005477/en/
[ Back To NFVZone's Homepage ]